INDOLE DERIVATIVES AS 5-HT1 AGONISTS

Inventors: John Eugene Macor, Salem, CT (US); Martin James Wythes, Sutton (GB)

Assignee: Pfizer Inc., New York, NY (US)

Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

Applied No.: 09/694,387
Filed: Oct. 23, 2000

Related U.S. Application Data

Division of application No. 09/659,799, filed on Apr. 14, 1998, now Pat. No. 6,150,388, which is a division of application No. 08/295,798, filed as application No. PCT/US93/01967 on Mar. 10, 1993, now Pat. No. 5,747,501, which is a continuation-in-part of application No. 07/864, 737, filed on Apr. 7, 1992, now abandoned.

Int. Cl.7 A61K 31/422; C07D 413/14
U.S. Cl. 514/323; 546/201
Field of Search 548/468; 546/201; 514/323

References Cited

U.S. PATENT DOCUMENTS

4,855,314 A 8/1989 Oxford et al. 514/415
5,208,248 A 5/1993 Baker et al. 514/364
5,498,626 A 3/1996 Macor et al. 514/414
5,545,644 A 8/1996 Macor et al. 514/323
5,559,129 A 9/1996 Macor et al. 514/323
5,559,246 A 9/1996 Macor et al. 548/468
5,578,612 A 11/1996 Macor et al. 514/323
5,594,014 A 1/1997 Macor et al. 514/364
5,639,752 A 6/1997 Macor et al. 514/245
5,717,102 A 2/1998 Macor et al. 548/131

FOREIGN PATENT DOCUMENTS

EP 0303506 8/1988
EP 0313979 10/1988
EP 0354777 8/1989
EP 0497512 8/1992
WO 918897 12/1991

OTHER PUBLICATIONS


Primary Examiner—Robert Gerstl
Attorney, Agent, or Firm—P. C. Richardson; P. H. Ginsburg; A. D. Joran
n is 0, 1, or 2; m is 0, 1, 2, or 3; Y and G are each independently oxygen or sulfur; Z is —O—, —S—, —NH, or —CH₂; R₁ is hydrogen, C₁ to C₈ alkyl, substituted C₁ to C₈ alkyl substituted with one hydroxy, C₁ to C₈ alkenyl, C₁ to C₈ alkynyl, aryl, C₁ to C₃ alkylaryl, C₁ to C₃ alkylheteroaryl, or -Q-R₂; R₂ and R₃ are each independently hydrogen, C₁ to C₈ alkyl, aryl, C₁ to C₃ alkylaryl, or C₁ to C₃ alkylheteroaryl; R₄ is cyano, trifluoromethyl, —COR₆, —CO₂R₆, —CONR₆R₁₀, —OR₆, —SO₂NR₆R₁₀, or —S(O)₂R₆; R₆ and R₁₀ are each independently hydrogen, C₁ to C₈ alkyl, C₁ to C₃ alkylaryl, aryl, or R₆ and R₁₀ may together be taken to form a three- to seven-membered alkyl ring or a three- to seven-membered heteroalkyl ring having 1 heteroatom of O; Q is C₁ to C₃ alkyl; R₁₁ is hydrogen, —OR₁₁, or —NHCOR₁₁; R₁₁ is hydrogen, C₁ to C₈ alkyl, aryl, or C₁ to C₅ alkyl-aryl; q is 0, 1, or 2; a first chiral carbon is designated by #; and the above aryl groups and the aryl moieties of the above alkyl-aryl groups are independently selected from phenyl and substituted phenyl, wherein said substituted phenyl may be substituted with one to three groups selected from C₁ to C₈ alkyl, halogen, hydroxy, cyano, carboxamide, nitro, and C₁ to C₈ alkoxy, and the pharmaceutically acceptable salts thereof.

These compounds are useful in treating migraine and other disorders are now. These compounds are useful psychotherapeutics and are potent serotonin (5-HT₄) agonists and may be used in the treatment of depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain, and chronic paroxysmal hemicrania and headache associated with vascular disorders, and other disorders arising from deficient serotonergic neurotransmission. The compounds can also be used as centrally acting antihypertensives and vasodilators.

16 Claims, No Drawings
INDOLE DERIVATIVES AS 5-HT1 AGONISTS

This is a division of U.S. Ser. No. 09/059,799 filed Apr. 14, 1998 now U.S. Pat. No. 6,156,388 which, in turn, is a division of U.S. Ser. No. 08/295,798 filed Sep. 16, 1994 now U.S. Pat. No. 5,747,501 which, in turn, is the national phase of application No. PCT/US93/01667 filed on Mar. 10, 1993 which, in turn, is a continuation-in-part of U.S. Ser. No. 07/864,737 filed on Apr. 7, 1992 now abandoned from which priority is claimed from both applications.

BACKGROUND OF THE INVENTION

The present invention relates to indole derivatives, to processes and intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The active compounds of the present invention are useful in treating migraine and other disorders.

U.S. Pat. Nos. 4,839,377 and 4,855,314 and European Patent Application Publication Number 313397 refer to 5-substituted 3-aminoalkyl indoles. The compounds are said to be useful for the treatment of migraine.

British Patent Application 0402079 refers to 3-aminoalkyl-1H-indole-5-thioamides and carboxamides. The compounds are said to be useful in treating hypertension, Raymond’s disease and migraine.

European Patent Application Publication Number 303506 refers to 3-poly-hydroxyalkyl-5-substituted-1H-indoles. The compounds are said to have 5-HT1 receptor agonist and vasoconstrictor activity and to be useful in treating migraine.

European Patent Application Publication Number 354777 refers to N-piperidinyl-indolyl-alkyl-alkane sulfonamide derivatives. The compounds are said to have 5-HT1 receptor agonist and vasoconstrictor activity and to be useful in treating cephalic pain.

European Patent Applications Publication Numbers 438230, 494774, and 497512 refers to indole-substituted five-membered heteroaromatic compounds. The compounds are said to have 5-HT1-like receptor agonist activity and to be useful in the treatment of migraine and other disorders for which a selective agonist of these receptors is indicated.

International Patent Application PCT/GB91/00908 and European Patent Application No. 313397A refers to 5-heterocyclic indole derivatives. The compounds are said to exhibit properties useful in the treatment and prophylaxis of migraine, cluster headache, and headache associated with vascular disorders. These compounds are also said to have “5-HT1-like” receptor agonism.

SUMMARY OF THE INVENTION

The present invention relates to compounds of the formula

\[ W-(CH_2)_n Y \]

where \( W \) is

(i) \[ \text{Substituted C to C alkyl} \]
(ii) \[ \text{Substituted C to C alkyl substituted with one hydroxy} \]
(iii) \[ \text{C to C alkenyl} \]
(iv) \[ \text{C to C alkyl} \]
(v) \[ \text{C to C alkyl substituted with one hydroxy} \]

n is 0, 1, or 2; m is 0, 1, 2, or 3; Y and G are each independently oxygen or sulfur; Z is \(-\text{O-}, -\text{S-}, -\text{NH}, \) or \(-\text{CH}_2-\); \( R_1 \) is hydrogen, \( C_1 \) to \( C_3 \) alkyl, substituted \( C_1 \) to \( C_5 \) alkyl substituted with one hydroxy, \( C_3 \) to \( C_6 \) alkenyl, \( C_3 \) to \( C_6 \) alkenyl.
to C₈ alkynyl, aryl, C₆ to C₈ alkylaryl, C₆ to C₈ alkylheteroaryls, or -OR₂; R₆ and R₇ are each independently hydrogen, C₂ to C₈ alkyl, aryl, C₂ to C₈ alkylaryl, or C₂ to C₈ alkylheteroaryls; R₈ is cyano, trifluoromethyl, -COR₉, -CO₂R₀, -CONR₉R₁₀, -OR₀, -SO₂NR₉R₁₀, or -(SO₂)₉R₈ and R₉ are each independently hydrogen, C₂ to C₈ alkyl, C₂ to C₈ alkylaryl, or R₀, and R₁₀ may together be taken to form a three- to seven-membered alkyl ring or a three- to seven-membered heteroaryl ring having 1 heteroatom of O; R₁₁ is hydrogen, -OR₁₂, or -NHCOR₁₂; R₁₂ is hydrogen, C₂ to C₈ alkyl, aryl, or C₂ to C₈ alkylaryl; q is 0, 1, or 2; R₁₃ is C₆ to C₈ alkyl; a first chiral carbon is designated by #; and the above aryl groups and the aryl moieties of the above alkyl-aryl groups are independently selected from phenyl and substituted phenyl, wherein said substituted phenyl may be substituted with one to three groups selected from C₂ to C₈ alkyl, halogen (e.g., fluorine, chlorine, bromine or iodine), hydroxy, cyano, carboxamide, nitro, and C₂ to C₈ alkoxy, and the pharmaceutically acceptable salts thereof. These compounds are useful in treating migraine and other disorders.

The compounds of the invention include all optical isomers of formula I (e.g., R and S stereoselectivity at any chiral site) and their racemic, diastereomeric, or epimeric mixtures. The epimers with the S absolute configuration at the chiral carbon site designated by # in formula I are preferred. When R₁₁ is hydrogen, the epimers with the R absolute configuration at the chiral carbon site designated by an asterisk in formula I are preferred. When R₁₂ is -OR₁₂ or -NHCOR₁₂ and n is 0 or 1, the epimers with the S absolute configuration at the chiral carbon site designated by an asterisk in formula I are preferred. When R₁₁ is -OR₁₂ or -NHCOR₁₂ and n is 2, the epimers with the R absolute configuration at the chiral carbon site designated by an asterisk in formula I are preferred. When R₁₁ is -OR₁₂ or -NHCOR₁₂ and n is O, the cis epimers [(2S, 3S) absolute configuration in the azetidine ring] are particularly preferred. When R₁₁ is -OR₁₂ or -NHCOR₁₂ and n is 1, the cis epimers [(2S, 4R) absolute configuration in the pyrrolidine ring] are particularly preferred. When R₁₁ is -OR₁₂ or -NHCOR₁₂ and n is 2, the cis epimers [(2R, 5R) absolute configuration in the piperidine ring] are particularly preferred.

Unless otherwise indicated, the alkyl, aryl, and alkynyl groups referred to herein, as well as the alkyl and alkylene moieties of other groups referred to herein (e.g. alkoxy), may be linear or branched, and they may also be cyclic (e.g. cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl) or be linear or branched and contain cyclic moieties.

Preferred compounds of the invention are compounds of the formula I wherein W is (i), (ii), or (iii); n is 1; m is 1; R₁ is hydrogen, C₁ to C₈ alkyl, or -CH₂CH₂OH; R₂ is hydrogen; and R₃ is hydrogen or -CH₃Ph (P=phenyl). Of the foregoing preferred compounds, the epimers with the S optical configuration at the chiral carbon designated by # in formula I are more preferred. Of the foregoing preferred compounds, when R₁₁ is hydrogen, the epimers with the R absolute configuration at the chiral carbon site designated by an asterisk in formula I are more preferred. Of the foregoing preferred compounds, when R₁₁ is -OR₁₂ or -NHCOR₁₂, the epimers with the S absolute configuration at the chiral carbon site designated by an asterisk in formula I are more preferred. Of the foregoing preferred compounds, when R₁₁ is -OR₁₂ or -NHCOR₁₂, the cis epimers [(2S, 4R) absolute configuration in the pyrrolidine ring] are particularly preferred.

The following compounds are particularly preferred: 3-[N-(2-Methoxyethyl)pyrrolidin-2-ylmethyl]-5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indole; 5-(2-Oxo-1,3-oxazolidin-4-ylmethyl)-3-(pyrrolidin-2-ylmethyl)-1H-indole; and 3-(N-Methylpyrrolidin-2-ylmethyl)-5-(2-oxo-1,3-oxazolidin-4-RS-ylmethyl)-1H-indole.

The present invention also relates to a pharmaceutical composition for treating a condition selected from hypertension, depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain, and chronic paroxysmal hemicrania and headache associated with vascular disorders comprising an amount of a compound of the formula I or a pharmaceutically acceptable salt thereof effective in treating such condition and a pharmaceutically acceptable carrier.

The present invention also relates to a method for treating a condition selected from hypertension, depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain, and chronic paroxysmal hemicrania and headache associated with vascular disorders comprising administering to a mammal (e.g., a human) requiring such treatment an amount of a compound of the formula I or a pharmaceutically acceptable salt thereof effective in treating such condition.

The present invention also relates to a pharmaceutical composition for treating disorders arising from deficient serotonergic neurotransmission (e.g., depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain and chronic paroxysmal hemicrania and headache associated with vascular disorders) comprising administering to a mammal (e.g., a human) requiring such treatment an amount of a compound of the formula I or a pharmaceutically acceptable salt thereof effective in treating such condition.

The present invention also relates to a method for treating disorders arising from deficient serotonergic neurotransmission (e.g., depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain and chronic paroxysmal hemicrania and headache associated with vascular disorders) comprising administering to a mammal (e.g., a human) requiring such treatment an amount of a compound of the formula I or a pharmaceutically acceptable salt thereof effective in treating such condition.

The present invention also relates to a compound of the formula

```
\[ \text{W} \text{CO}_2\text{R}_5 \]
```

where W is
(i) Y

(ii) Y

(iii) Y

(iv) Y

(v) Y

(vi) Y

(vii) Y

---

The present invention also relates to a compound of the formula

\[ \text{(III)} \]

where W is

\[ \text{(i)} \]

---

z is 0, 1, or 2; m is 0, 1, 2, or 3; Y and G are each independently oxygen or sulfur; Z is \(-\text{O-}, -\text{S-}, -\text{NH}, -\text{CH}_2\); R and R\(_2\) are each independently hydrogen, C\(_1\) to C\(_5\) alkyl, aryl, C\(_1\) to C\(_3\) alkylaryl, and C\(_1\) to C\(_3\) alkyletheroaryl; R\(_6\) is C\(_1\) to C\(_5\) alkyl, aryl, or C\(_1\) to C\(_5\) alkylaryl (preferably benzyl); R\(_{11}\) is hydrogen, \(-\text{OR}_{12}\), or \(-\text{NHCOR}_{12}\); R\(_{12}\) is hydrogen, C\(_1\) to C\(_5\) alkyl, aryl, or C\(_1\) to C\(_5\) alkyl-aryl; a first chiral carbon is designated by an asterisk in formula II; a second chiral carbon is designated by \#; and the above aryl groups and the aryl moieties of the above alkyl-aryl groups are independently selected from phenyl and substituted phenyl, wherein said substituted phenyl may be substituted with one to three groups selected from C\(_1\) to C\(_5\) alkyl, halogen (e.g., fluorine, chlorine, bromine or iodine), hydroxy, cyano, carboxamido, nitro, and C\(_1\) to C\(_4\) alkoxy.

The epimers with the S absolute configuration at the chiral carbon site designated by \# in formula II are preferred. When R\(_{11}\) is hydrogen, the epimers with the R absolute configuration at the chiral carbon site designated by an asterisk in formula II are preferred. When R\(_{11}\) is \(-\text{OR}_{12}\) or \(-\text{NHCOR}_{12}\) and n is O or 1, the epimers with the S absolute configuration at the chiral carbon site designated by an asterisk in formula II are preferred. When R\(_{11}\) is \(-\text{OR}_{12}\) or \(-\text{NHCOR}_{12}\) and n is 2, the cis epimers \([2S, 3S]\) absolute configuration in the piperidine ring are particularly preferred. The compounds of formula II are useful as intermediates in preparing compounds of formula I.
n is 0, 1, or 2; m is 0, 1, 2, or 3; Y and G are each independently oxygen or sulfur; Z is —O—, —S—, —NH—, or —CH₂; R₂ and R₃ are each independently hydrogen, C₁ to C₅ alkyl, aryl, C₁ to C₅ alkylaryl, or C₁ to C₅ alkylhetereoaryl; R₄ is C₁ to C₅ alkyl, aryl, or C₁ to C₅ alkylaryl (preferably benzyl); R₅ is halogen [preferably bromide]; R₆ is —CO₂F₃, —SO₂CH₃, —SO₂Ph, or —CO₂(CH₃)₂; R₁₁ is hydrogen, —OR₁₂, or —NHCOR₁₂; R₁₂ is hydrogen, C₁ to C₅ alkyl, aryl, or C₁ to C₅ alkylaryl; a first chiral carbon is designated by an asterisk; a second chiral carbon is designated by #; and the above aryl groups and the aryl moieties of the above alkyl-aryl groups are independently selected from phenyl and substituted phenyl, wherein said substituted phenyl may be substituted with one to three groups selected from C₁ to C₅ alkyl, halogen, hydroxy, cyano, carboxamido, nitro, and C₁ to C₅ alkyl oxy. The epimers with the S absolute configuration at the chiral carbon site designated by # in formula XVII are preferred. When R₁₁ is hydrogen, the epimers with the R absolute configuration at the chiral carbon site designated by an asterisk in formula XIII are preferred. When R₁₁ is —OR₁₂ or —NHCOR₁₂ and n is 0 or 1, the epimers with the S absolute configuration at the chiral carbon site designated by an asterisk in formula XIII are preferred. When R₁₁ is —OR₁₂ or —NHCOR₁₂ and n is 2, the epimers with the R absolute configuration at the chiral carbon site designated by an asterisk in formula XIII are preferred. When R₁₁ is —OR₁₂ or —NHCOR₁₂ and n is 0, the cis epimers [2S, 3S] absolute configuration in the azetidine ring] are particularly preferred. When R₁₁ is —OR₁₂ or —NHCOR₁₂ and n is 1, the cis epimers [2S, 4R] absolute configuration in the pyrrolidine ring] are particularly preferred. When R₁₁ is —OR₁₂ or —NHCOR₁₂ and n is 2, the cis epimers [2R, 5R] absolute configuration in the piperidine ring] are particularly preferred. The compounds of formula XVII are useful as intermediates in preparing compounds of formula I.

The present invention also relates to a compound of the formula

\[
\text{XIV}
\]

n is 0, 1, or 2; R₁ is hydrogen, C₁ to C₅ alkyl, substituted C₁ to C₅ alkyl substituted with one hydroxy, C₁ to C₅ alkyl, C₁ to C₅ alkylaryl, aryl, or C₁ to C₅ alkylaryl; R₂ is cyano, trifluoromethyl, —COR₇, —CONR₁₁R₁₂, —OR₁₂, —SO₂NR₁₁R₁₂, or —SO₂(R₂), R₆ and R₇ may each be hydrogen, C₁ to C₅ alkyl, C₁ to C₅ alkylaryl, aryl, or C₁ to C₅ alkylaryl; R₁₂ is hydrogen, C₁ to C₅ alkyl, aryl, or C₁ to C₅ alkylaryl; R₁₃ is C₁ to C₅ alkyl, aryl, or C₁ to C₅ alkylaryl; q is 0, 1, or 2; Q is C₁ to C₅ alkyl; a first chiral carbon is designated by an asterisk; and the above aryl groups and the aryl moieties of the above alkyl-aryl groups are independently selected from phenyl and substituted phenyl, wherein said substituted phenyl may be substituted with one to three groups selected from C₁ to C₅ alkyl, hydroxy, cyano, carboxamido, nitro, and C₁ to C₅ alkyl oxy.
halogen, hydroxy, cyano, carboxamido, nitro, and C to C alkoxy. The epimers with the S absolute configuration at the chiral carbon site designated by # in formula XIV are preferred. When R₆ is hydrogen, the epimers with the R absolute configuration at the chiral carbon site designated by an asterisk in formula XIV are preferred. When R₁₂ is —OR₁₂ or —NHCOR₁₂ and n is 0 or 1, the epimers with the S absolute configuration at the chiral carbon site designated by an asterisk in formula XIV are preferred. When R₁₁ is —OR₁₁ or —NHCOR₁₁ and n is 2, the epimers with the R absolute configuration at the chiral carbon site designated by an asterisk in formula XIV are preferred. When R₁₁ is —OR₁₁ or —NHCOR₁₁ and n is 2, the cis epimers [2(S), 3(S) absolute configuration in the azetidine ring] are particularly preferred. When R₁₁ is —OR₁₁ or —NHCOR₁₁ and n is 1, the cis epimers [2(S), 4(R) absolute configuration in the pyrrolidine ring] are particularly preferred. When R₁₁ is —OR₁₁ or —NHCOR₁₁ and n is 2, the cis epimers [2(R), 5(R) absolute configuration in the piperidine ring] are particularly preferred.

The compounds of formula XIV are useful as intermediates in preparing compounds of formula XVII.

**DETAILED DESCRIPTION OF THE INVENTION**

The compounds of the present invention are prepared via the following reaction scheme.

**Compounds of formula III can be prepared by the Mitsunobu coupling reaction of compounds of formulas IV and V where W, n, m, R₃, R₄ (preferably bromine or iodine), and R₅ (preferably trifluoroacetyl [—COF₂] and R₆ are as defined above using a phosphine and an azodicarboxylate in an inert solvent. Suitable phosphines include trialkyl phosphines and triarylphosphines, preferably triphenylphosphine. Suitable azodicarboxylates include dialkyl azodicarboxylates, preferably diethyl diazodicarboxylate. Suitable solvents include methylene chloride, ethers, (tetrahydrofuran, diethyl ether, and 1,4-dioxane), N,N-dimethylformamide and acetonitrile. The preferred solvent is tetrahydrofuran. The reaction is conducted at a temperature of from about 0°C to about 65°C, most preferably at about 25°C.**

Compounds of formula II can be prepared by the transition metal catalyzed cyclization of compounds of the formula III, wherein W, n, m, R₃, R₄ (preferably bromine or iodine), and R₅ (preferably trifluoroacetyl [—COF₂] and R₆ are as defined above in a suitable inert solvent with a phase transfer catalyst and a base. Suitable transition metal catalysts include palladium salts such as palladium (II) acetate or palladium (II) chloride and rhodium salts, such as tris(triphenyl)rhodium (I) chloride. The preferred catalyst is palladium (II) acetate. Suitable solvents include N,N-dimethylformamide, acetonitrile, and N-methylpyrrolidone. The preferred solvent is N,N-dimethylformamide. Suitable phase transfer catalysts include tetraalkylammonium halides, preferably tetra-n-butylammonium chloride. Suitable bases include tertiary amines, sodium hydrogen carbonate, and sodium carbonate. The preferred base is triethylamine. The reaction is conducted at a temperature of from about 60°C. to about 180°C, preferably from about 80°C. to about 100°C.

Compounds of formula IA wherein R₇ is hydrogen are prepared by catalytic reduction of a compound of the formula II, wherein W, n, m, and R₃ are as defined above, R₄ is preferably benzyl, under an atmosphere of hydrogen, preferably at a pressure of from about 1 to about 3 atmospheres, or using a hydrogen source such as ammonium formate or formic acid in an inert solvent. Suitable catalysts include palladium on carbon, Raney nickel, and platinum oxide. The preferred catalyst is palladium on carbon. Suitable solvents include C₁ to C₆ alcohols, N,N-dimethylformamide, ethyl acetate, and acetonitrile. The preferred solvent is ethanol. The reaction is conducted at a temperature of from about 0°C. to about 60°C., preferably about 25°C.
Compounds of formula IX can be prepared by reacting a compound of formula XI wherein W and m are as defined above with either chlorine, bromine, or iodine in an inert solvent with a base. Reaction with bromine is preferred. Suitable solvents include C₆ to C₈ alcohols, methylene chloride, chloroform, or carbon tetrachloride. The preferred solvent is methanol. Suitable bases include triethylamine, pyridine, sodium carbonate, and sodium hydrogen carbonate. The preferred base is sodium hydrogen carbonate. The reaction is conducted at a temperature of from about 0°C to about 65°C, preferably at about 25°C.

Compounds of formula IV can be prepared by reacting a compound of formula IX wherein W and m are as defined above with the acid chloride or symmetrical anhydride of the formula R₆OH in an inert solvent with a base. The preferred acid chloride or anhydride is trifluoroacetic anhydride. Suitable solvents include methylene chloride, chloroform as well as ethers, including tetrahydrofuran, diethyl ether and 1,4-dioxane. The preferred solvent is methylene chloride. Suitable bases include triethylamine, pyridine, and sodium hydrogen carbonate. The preferred base is pyridine. The reaction is conducted at a temperature of from about 0°C to about 65°C, preferably at about 25°C.

Compounds of the formula XI can be prepared using methods known to one skilled in the art, such as, for example, as outlined in International Patent Application No. PCT/GB91/00908 and European Patent Application No. 313397A.

Compounds of the formula V can be prepared using the following reaction scheme:

Compounds of the formula VI can be prepared using the Wittig reaction in an inert solvent involving compounds of the formulas VII and VIII wherein n, R₈, and R₁₁ are defined as above and R₆ is C₉ to C₁₈ alkyl, aryl, or C₁ to C₃ alkylaryl. Suitable solvents include ethers such a diethyl ether, tetrahydrofuran, and 1,4-dioxane. Tetrahydrofuran is the preferred solvent. The reaction is conducted at a temperature of from about −78°C to about 80°C, preferably at about 25°C.

Compounds of the formula V can be prepared from a hydride reduction of a compound of formula VI wherein n, R₈, R₉, and R₁₁ are as defined above with a hydride reducing agent in an inert solvent. Suitable hydride reducing agents include lithium aluminum hydride, lithium borohydride, sodium borohydride, and disobutylaluminum hydride. The preferred reagent is diisobutylaluminum hydride. Suitable solvents include ethers such as diethyl ether, tetrahydrofuran, 1,4-dioxane and 1,2-dimethoxyethane. The preferred solvent is tetrahydrofuran. The reduction is conducted at a temperature of from about −100°C to about 0°C, preferably from about −80°C to about −70°C.
Compounds of the formula VII can be prepared using methods known in the art, such as, for example, as outlined in S. Kiyooka, et al., J. Org. Chem., 5409 (1989) and Y. Hamada, et al., Chem. Pharm. Bull., 1921 (1982).

Compounds of the formula VIII are either commercially available or can be prepared using methods known in the art, such as, for example, as outlined in L. Fieser and M. Fieser, Reagents for Organic Synthesis, John Wiley & Sons New York, Vol. 1, p. 112 (1967).

Compounds of formula I wherein W is (i), Z is 0, m=1, R₁ and R₂ are each hydrogen may also be prepared via the following scheme:

where W is (i), Z=0, m=1, R₁=H, R₂=H.

Compounds of formula XII wherein n, R₃, R₄, and R₅ are as defined above and K is chloro, bromo or iodo (preferably bromo) can be prepared by coupling a compound of formula XII with a dehydroalanine derivative of formula XIII wherein R₆ is as defined above (preferably benzyl) and R₇ is as defined above (preferably methyl), using the Heck reaction known in the art. Suitable palladium catalysts for the Heck reaction include palladium salts such as palladium (II) acetate, in the presence of a phosphine such as triphenylphosphine or tri-o-tolyphosphine, preferably tri-o-tolyphosphine. Suitable bases for the Heck reaction include trialkylamines, preferably triethylamine, and suitable inert solvents include acetonitrile and N,N-dimethylformamide, preferably acetonitrile. The reaction is conducted at a temperature of from about 60°C to about 150°C, preferably at the reflux temperature of the solvent.

Compounds of formula XV, wherein R₁₁, R₂₁, and n are as defined above, can be prepared from compounds of formula XIV wherein R₄ is preferably benzyl, by catalytic reduction under an atmosphere of hydrogen, preferably at a pressure of from about 1 to about 3 atmospheres, or by using a hydrogen source such as ammonium formate or formic acid in an inert solvent. Suitable catalysts for either of the above reactions include palladium on carbon, Raney nickel and platinum oxide, preferably palladium on carbon. Suitable solvents for either of the above reactions include C₂ to C₄ alcohols, N,N-dimethylformamide, ethyl acetate and acetonitrile. The preferred solvent is ethanol. Optionally the reaction may be conducted in the presence of an acid. Suitable acids include hydrochloric acid. Suitable solvents for use with the acid include all those mentioned previously in this paragraph, preferably ethanol. All of these reactions are conducted at a temperature of from about 0°C to about 60°C, preferably at about 25°C.

Compounds of formula XVI, wherein n, R₅, R₁₁, and K are as defined above, can be prepared from a compound of formula XV by reduction in an inert solvent. Suitable reducing agents include alkali metal borohydrides, such as sodium borohydride or lithium borohydride, or lithium aluminum hydride. The preferred reducing agent is sodium borohydride. Suitable solvents for borohydride reducing agents include C₁ to C₄ alcohols, preferably ethanol. Suitable solvents for lithium aluminum hydride reductions include ethers, such as tetrahydrofuran and diethyl ether, preferably tetrahydrofuran. The reaction is conducted at a temperature of from about 25°C to about 80°C, preferably at the reflux temperature of the solvent.

Compounds of formula I, wherein W is (i), Z=0, m=1, R₁=H, R₂=H, R₃=H, R₄=H, and K is chloro, bromo or iodo (preferably bromo) can be prepared using methods known in the art, such as, for example, as described in WO 9206973.

Compounds of formula XIV, wherein n, R₁₁, R₁₁, and R₅ are as defined above and R₆ is C₂ to C₅ alkyl, aryl, or C₁ to C₅ alkylaryl, can be prepared by coupling a compound of formula XII with a dehydroalanine derivative of formula XIII wherein R₆ is as defined above (preferably benzyl) and R₇ is as defined above (preferably methyl), using the Heck reaction known in the art. Suitable palladium catalysts for the Heck reaction include palladium salts such as palladium (II) acetate, in the presence of a phosphine such as triphenylphosphine or tri-o-tolyphosphine, preferably tri-o-tolyphosphine. Suitable bases for the Heck reaction include trialkylamines, preferably triethylamine, and suitable inert solvents include acetonitrile and N,N-dimethylformamide, preferably acetonitrile. The reaction is conducted at a temperature of from about 60°C to about 150°C, preferably at the reflux temperature of the solvent.

The compounds of the formula I which are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate a
compound of the formula I from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent, and subsequently convert the free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is obtained.

The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the base compounds of this invention are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate, lactate, citrate or acid citrate, tartrate or bitartrate, succinate, malate, fumarate, gluconate, saccharate, benzoate, methanesulfonate and pamoate [i.e., 1,1’-methylene-bis(2-hydroxy-3-naphthoic)] salts.

Those compounds of the formula I which are also acidic in solution, have the general formula R, contain a carboxylate, are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include the alkali metal or alkaline-earth metal salts and particular, the sodium and potassium salts. These salts are all prepared by conventional techniques. The chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the herein described acidic compounds of formula I. These non-toxic base salts include those derived from such pharmaceutically acceptable cations as sodium, potassium, calcium, magnesium, etc. These salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, they may also be prepared by mixing lower alkanoic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before. In either case, stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction of maximum product of yields of desired final product.

The compounds of the formula I and the pharmaceutically acceptable salts thereof (hereinafter, also referred to as the active compounds of the invention) are useful psychotherapeutics and are potent serotonin (5-HT(1A)) agonists and may be used in the treatment of depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, chronic paroxysmal hemiconia and headache associated with vascular disorders, pain, and other disorders arising from deficient serotonergic neurotransmission. The compounds can also be used as centrally acting antihypertensives and vasodilators.

The active compounds of the invention can be evaluated as anti-migraine agents by testing the extent to which they mimic sumatriptan in contracting the dog isolated saphenous vein strip [P. A. Humphrey et al., Br. J. Pharmacol., 94, 1128 (1988)]. This effect can be blocked by methiothepin, a known serotonin antagonist. Sumatriptan is known to be useful in the treatment of migraine and produces a selective increase in carotid vascular resistance in the anesthetized dog. It has been suggested [W. Fenwick et al., Br. J. Pharmacol., 96, 83 (1989)] that this is the basis of its efficacy. p The serotonin 5-HT(1A) agonist activity of the compounds of the present invention can be measured in vitro receptor binding assays as described for the 5-HT(1A) receptor using rat cortex as the receptor source and [3H]-OH-IPAT as the radioligand [D. Hoyer et al. Eur. J. Pharm., Vol. 118, 13 (1985)] and as described for the 5-HT(1D) receptor using bovine caudate as the receptor source and [3H]serotonin as the radioligand [R. E. Heuring and S. J. Peroutka, J. Neuroscience, Vol. 7, 894 (1987)] 5-HT(1A) agonist activity is defined by agents with affinities (IC50's) of 250 nM or less at either binding assay.

The compositions of the present invention may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers. Thus, the active compounds of the invention may be formulated for oral, buccal, sublingual, intranasal, parenteral (e.g., intravenous, intramuscular or subcutaneous) or rectal administration or in a form suitable for administration by inhalation or insufflation.

For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycylate); or wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additions such as suspending agents (e.g. sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters or ethyl alcohol); and preservatives (e.g. methyl or propyl p-hydroxybenzoates or sorbic acid).

For buccal and sublingual administration the composition may take the form of tablets or lozenges formulated in conventional manner.

The active compounds of the invention may be formulated for parenteral administration by injection, including using conventional catheterization techniques or infusion. Formulations for injection may be presented in unit dosage form e.g. in ampules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for reconstitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.

The active compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides. For intranasal administration or administration by inhalation, the active compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized
aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurized container or nebulizer may contain a solution or suspension of the active compound. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.

A proposed dose of the active compounds of the invention for oral, parenteral or buccal administration to the average adult human for the treatment of the conditions referred to above (e.g., migraine) is 0.1 to 200 mg of the active ingredient per unit dose which could be administered, for example, 1 to 4 times per day.

Aerosol formulations for treatment of the conditions referred to above (e.g., migraine) in the average adult are preferably arranged so that each metered dose or "puff" of aerosol contains 20 μg to 1000 μg of the compound of the invention. The overall daily does with an aerosol will be within the range 100 μg to 10 mg. Administration may be several times daily, for example, 2, 3, 4 or 8 times, giving for example, 1, 2 or 3 doses each time.

The following Examples illustrate how the compounds of the present invention can be prepared. Commercial reagents can be utilized without further purification. Room temperature refers to 20–25°C.

**EXAMPLE 1**

**General Procedure for the Alkylation of (R)-3-pyrollidin-2-ylmethyl-1H-indoles**

To a stirred solution of the (R)-3-pyrrolidin-2-ylmethyl-1H-indole (1.00 mmol) and triethylamine (0.126 g, 1.25 mmol, 1.25 eq) in either anhydrous methylene chloride, anhydrous acetonitrile, absolute ethanol, or 1-propanol (10 mL) at room temperature under nitrogen is added dry aspirin (2.25 mmol). The resulting reaction solution is then stirred under nitrogen at room temperature or heated at reflux for 1 to 2 hours, depending on substrate. The resulting reaction mixture is directly column chromatographed using silica gel (approximately 25 g) and elution with methylene chloride-methanol-ammonium hydroxide [9:1:0.1] to afford the title compound.

Using this procedure, the following compound was prepared:

3-{[N-(2-Methoxyethyl)]pyrrolidin-2-ylmethyl}-5-(2-oxo-1,3-oxazolidin-4-yl)methyl]-1H-indole

To a stirred solution of triphenylphosphine (0.655 g, 2.50 mmol, 1.25 eq) and diethylazodicarboxylate (0.39 mL, 2.48 mmol, 1.25 eq) in absolute ethanol (15 mL) is shaken under a hydrogen atmosphere (3 atm) for 4 to 24 hours, depending on substrate. The resulting reaction mixture is directly column chromatographed using silica gel (approximately 25 g) and elution with methylene chloride-methanol-ammonium hydroxide [9:1:0.1] to afford the title compound.

Using this procedure, the following compound was prepared:

3-{[N-(2-Methoxyethyl)]pyrrolidin-2-ylmethyl]-5-(2-oxo-1,3-oxazolidin-4-yl)methyl]-1H-indole

5-(2-oxo-1,3-oxazolidin-4-yl)methyl]-3-pyrrolidin-2-ylmethyl]-1H-indole and 2-bromoethyl methyl ether were used. Acetonitrile/ethanol (1:1) was the reaction solvent, and the reaction was heated at reflux for 3 hours. Column chromatography afforded the title compound (36%) as a light tan foam. 1H NMR (CD,OD) δ 110.9, 135.9, 127.2, 126.3, 123.8, 121.3, 118.5, 111.3, 109.2, 69.1, 68.1, 67.6, 60.9, 57.8, 54.6, 53.8, 40.4, 29.5, 27.2, 21.3, [α]23+43.6 (c=1, MeOH); FAB LRMS (m/z, relative intensity) 359 (23), 358 (MH+1, 100), 188 (26); EI LRMS (m/z, relative intensity) 357 (0.1), 355 (2), 143 (25), 128 (100); HRMS calculated for C29H29N3O3, 357.2054 found 357.2062.

**EXAMPLE 2**

**General Procedure for the Catalytic Reduction of 3-(N-Benzylxoxycarbonylpyrrolidin-2-ylmethyl)-1H-indoles Forming 3-(Pyrrolidin-2-ylmethyl)-1H-indoles**

A mixture of the 3-(N-benzylxoxycarbonylpyrrolidin-2-ylmethyl)-1H-indole (2.00 mmol) and 10% palladium on carbon (0.20 g) in absolute ethanol (15 mL) is shaken under a hydrogen atmosphere (3 atm) for 4 to 24 hours, depending on substrate. The resulting reaction mixture is filtered through diatomaceous earth, and the filtrate is evaporated under reduced pressure. The residue is column chromatographed using silica gel (approximately 50 g) and elution with a solution of methylene chloride-methanol-ammonium hydroxide [8:2:0.2] or other appropriate solvent system to afford the corresponding 3-(pyrrolidin-2-ylmethyl)-1H-indole.

Using this procedure, the following compound was prepared:

5-(2-Oxo-1,3-oxazolidin-4-ylmethyl)-3-(pyrrolidin-2-ylmethyl)-1H-indole

3-(N-Benzylxoxycarbonylpyrrolidin-2-ylmethyl)-5-(2-oxo-1,3-oxazolidin-4-yl)methyl]-1H-indole was used. Column chromatography afforded the title compound (89%) as an amorphous white solid: Rf=0.30 in methylene chloride-methanol-ammonium hydroxide [6:2:0.2]; 1H NMR (CD,OD) δ 7.43 (br s, 1H), 7.30 (d, J=8.5 Hz, 1H), 7.10 (s, 1H), 6.98 (dd, J=1.4 and 8.5 Hz, 1H), 4.90 (approximately 3H, exchanged), 4.36–3.51 (m, 2H), 3.52–3.42 (m, 1H), 3.10–3.22 (m, 6H), 2.01–1.74 (m, 3H), 1.48–1.46 (m, 1H); 13C NMR (CD,OD) δ 162.3, 137.3, 129.2, 127.5, 124.5, 124.0, 119.9, 112.8, 112.6, 70.7, 61.2, 47.0, 46.7, 42.2, 32.1, 31.1, 25.5; LRMS (m/z, relative intensity) 299 (M+1, 230 (31), 144 (18), 70 (100); HRMS calculated for C29H29N3O3, 396.2135, found 396.2128.

**EXAMPLE 3**

**General Procedure for the Formation of 3-(Pyrrolidin-2-ylmethyl)-1H-indoles Via the Palladium Catalyzed Cyclization of 1-(N-Pyrrolidin-2-yl)-3-(N-(2-halophenyl))-N-trifluoroacetylamino)propanes**

A mixture of the 1-(pyrrolidin-2-yl)-3-(N-(2-halophenyl))-N-trifluoroacetylamino)propane (2.00 mmol), tetrabutylammonium chloride (2.00 mmol), and palladium (II) acetate (0.089 g, 0.40 mmol, 0.2 eq) in a solution of triethylamine (8 mL) and anhydrous N,N-dimethylformamide (4 mL) is heated at reflux under nitrogen for 2 hours. The resulting reaction mixture is evaporated under reduced pressure, and the residue is partitioned between ethyl acetate (25 mL) and water (25 mL). The ethyl acetate layer is removed, and the aqueous layer is extracted with ethyl acetate (25 mL). The organic extracts are combined, dried (MgSO4), and evaporated under reduced pressure. The residue is column chromatographed using silica gel (approximately 50 g) and elution with an appropriate solvent system to afford the corresponding 3-(pyrrolidin-2-ylmethyl)-1H-indole.

Using this procedure, the following compound was prepared:

3-(N-Benzylxoxycarbonylpyrrolidin-2-ylmethyl)-5-(2-oxo-1,3-oxazolidin-4-yl)methyl]-1H-indole

1-(N-Benzylxoxycarbonylpyrrolidin-2-yl)-3-(N-(2-bromo-4-(2-oxo-1,3-oxazolidin-4-yl)methyl)phenyl)-N-trifluoroacetylamino)propane was used. Column chromatography using 1:1 ethyl acetate/hexanes afforded the title compound (40%) as a clear, colorless oil: Rf=0.50 in ethyl acetate; LRMS (m/z, relative intensity) 433 (10, M+); 398 (4), 298 (19), 204 (31), 160 (67), 143 (20), 91 (100); HRMS calculated for C29H29N3O3, 433.2003, found 433.2018.

**EXAMPLE 4**

**General Procedure for the Formation 1-(Pyrrolidin-2-yl)-3-(N-(2-halophenyl))-N-trifluoroacetylamino)propanes from the Mitsunobu Coupling of 2-Halo-N-trifluoroacetylanelines with 1-(pyrrolidin-2-yl)-3-hydroxypropanes**

To a stirred solution of triphenylphosphine (0.655 g, 2.50 mmol, 1.25 eq) and diethyl azodicarboxylate (0.39 mL, 2.48 mmol, 1.25 eq) in anhydrous benzene (15 mL) is added the 1-(halophenyl)-2,2-dichloroethanol (2.00 mmol). The solution is heated at reflux for 4 to 24 hours. The resulting reaction mixture is directly column chromatographed using silica gel (approximately 50 g) and elution with an appropriate solvent system to afford the corresponding 3-(pyrrolidin-2-ylmethyl)-1H-indole.
mmol, 1.25 eq) in anhydrous tetrahydrofuran (15 mL) at 0° C. Under a nitrogen atmosphere is added a mixture of 2-halo-N-trifluoroacetylamidine (2.5 mmol, 1.25 eq) in anhydrous tetrahydrofuran (5 mL). This is then followed by the dropwise addition of a solution of 1-(pyrrolidin-2-yl)-3-hydroxypropene (R, or S, or racemate, 2.00 mmol) in anhydrous tetrahydrofuran (5 mL). The reaction solution is slowly warmed to 25° C. over the course of 2 hours, and then stirred at 25° C. under a nitrogen atmosphere for an additional 12 hours. The resulting reaction solution is evaporated under reduced pressure, and the residue is column chromatographed using silica gel (approximately 150 g) and elution with an appropriate solvent system to afford the corresponding 1-(pyrrolidin-2-yl)-3-(N-(2-halophenyl)-N-trifluoroacetyl-amino)propene.

Using this procedure, the following compound was prepared:

1-(N-Benzyloxy carbonyl pyrrolidin-2-yl)-3-[N-(2-bromo-4-(2-oxo-1,3-oxazolidin-4-yl)methyl) phenyl] N-trifluoroacetylaminopropene

(R)-1-(N-Benzylxocarbonyl pyrrolidin-2-yl)-3-hydroxypropene and 2-bromo-4-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1-trifluoroacetylamino benzene were used. Column chromatography afforded the title compound (100%) as a clear, colorless oil; Rf=0.45 in ethyl acetate/1% acetic acid (m/z, relative intensity) 612 (M+1, 100), 588 (10), 566 (8), 502 (3), 476 (4), 279 (100); HRMS calculated for C_{28}H_{29}BrNO_{3} 609.1087, found 609.0952.

**EXAMPLE 5**

(R)-3-Hydroxy-1-(N-methylpyrrolidin-2-yl)propene

To a stirred solution of lithium aluminum hydride (0.73 g, 19.24 mmol, 2 equivalents) in anhydrous tetrahydrofuran (20 mL) at 0° C. was added dropwise a solution of (R)-1-(N-benzyloxycarbonylpiprrolidin-2-yl)-3-hydroxypropene (2.30 g, 8.60 mmol) in anhydrous tetrahydrofuran (20 mL). The resulting reaction mixture was heated at reflux under nitrogen for 3.5 hours. The resulting mixture was then cooled, and sodium sulfate dehydrate (10 g) was added slowly with caution. This mixture was stirred at room temperature under nitrogen for 1 hour, and then ethyl acetate (100 mL) and water (1 mL) was added. The resulting mixture was stirred at room temperature under nitrogen overnight. The mixture was then filtered through Celite®, and the filtrate was evaporated under reduced pressure. Column chromatography of the residual oil using silica gel (approximately 200 g) and elution with methylene chloride/methanol/ammonium hydroxide (9:1:0.1) afforded the title compound (1.13 g, 8.00 mmol, 91%) as a colorless liquid; 1H NMR (CDCl₃, δ 7.40-7.25 (m, 5H), 7.55-7.53 (m, 2H), 5.20-5.09 (m, 2H), 4.38 (br s, 1H), 4.06 (br s, 1J=13.7 Hz, 2H), 3.45 (br t, 1J=7.0 Hz, 1H), 2.01-1.68 (m, 4H); [α]^{25}_{D}^{25}+34° (MeOH, c=1) 1.00; HRMS calculated for C_{15}H_{28}NO₃ 261.1356, found 261.1356.

**EXAMPLE 7**

Ethyl (R)-3-(N-Benzylxocarbonyl pyrrolidin-2-yl)-2-propenoate

To a stirred solution of N-carbobenzyloxypropyridine-2-carboxaldehyde (1.17 g, 5.00 mmol) in anhydrous tetrahydrofuran at -78° C. was added (carboxethoxymethylene) triphenylphosphorane (2.09 g, 6.00 mmol, 1.2 eq) as a solid portionwise. The resulting reaction mixture was stirred at room temperature under nitrogen for 2 hours, and then heated at reflux under nitrogen for 1 hour. The reaction mixture was evaporated under reduced pressure and the residue was column chromatographed using silica gel (approximately 100 g) and elution with 20% diethyl ether in hexanes to afford the title compound as a clear, colorless oil (1.11 g, 3.65 mmol, 73%); 1H NMR (CDCl₃-d, δ 7.34-7.25 (m, 5H), 6.89-6.76 (m, 1H), 5.88-5.74 (m, 1H), 5.18-5.05 (m, 2H), 4.60-4.43 (m, 1H), 4.17 (q, J=7.1 Hz, 2H), 3.55-3.40 (m, 2H), 2.11-2.00 (m, 1H), 1.90-1.75 (m, 3H), 1.28 (t, J=7.1 Hz, 3H). 13C NMR (CDCl₃) [Note: due to slow nitrogen inversion two conformers of the products are seen by NMR spectroscopy] δ 166.3, 154.7, 147.9, 147.4, 136.6, 128.4, 127.9, 129.0, 66.9, 65.8, 60.4, 58.1, 57.7, 46.8, 46.4, 31.6, 30.8, 23.6, 22.8, 22.6, 15.3, 14.2.

**EXAMPLE 8**

General Synthesis of 2-Halo-N-trifluoroacetylaminelines

To a stirred mixture of N-trifluoroacetylamidine (2.00 mmol) and sodium hydrogen carbonate (0.21 g, 2.50 mmol, 1.25 eq) in methanol (10 mL) at 0° C. is added dropwise bromine (0.113 mL, 2.19 mmol, 1.1 eq). The resulting reaction mixture is then stirred at 25° C. for 30 minutes. The reaction mixture is then evaporated under reduced pressure, and the residue is placed in water made acidic to pH 3 with HCl (10 mL). This aqueous mixture is extracted with ethyl acetate (3×15 mL). The extracts is combined, dried (MgSO₄), and evaporated under reduced pressure. The residue is column chromatographed using silica gel (approximately 50 g) and elution with an appropriate solvent system to afford the corresponding 2-bromo-N-trifluoroacetylamine.

Using this procedure, the following compound was prepared:

2-Bromo-4-(2-oxo-1,3-oxazolidin-4-ylmorphyl)-1-trifluoroacetylamino benzene

4-(2-Oxo-1,3-oxazolidin-4-ylmethyl)-1-trifluoroacetylamino benzene was used. Column chromatography of the residue with diethyl ether/hexanes [1:1] afforded the title compound as a yellow solid (414 g, 54%): 1H NMR (CDCl₃) δ 7.40-7.25 (m, 5H), 7.55-7.53 (m, 2H), 5.20-5.09 (m, 2H), 4.38 (br s, 1H), 4.06 (br s, 1J=13.7 Hz, 2H), 3.45 (br t, 1J=7.0 Hz, 1H), 2.03-1.68 (m, 4H); [α]^{25}_{D}^{25}+34° (MeOH, c=1); HRMS calculated for C_{15}H_{28}NO₃ 261.1356, found 261.1356.

**EXAMPLE 9**

The reaction solution was stirred at -78° C. under nitrogen for 30 minutes. The reaction solution was then allowed to warm to room temperature over the course of 2 hours. A saturated solution of sodium hydrogen carbonate (50 mL) was added, and the aqueous mixture was extracted with ethyl acetate (3×50 mL). The extracts were combined, dried (MgSO₄), and evaporated under reduced pressure. Column chromatography of the residue with diethyl ether/hexanes [1:1] afforded the title compound as a clear colorless oil (1.41 g, 5.40 mmol, 54%): 1H NMR (CDCl₃) δ 7.40-7.25 (m, 5H), 7.55-7.53 (m, 2H), 5.26-5.09 (m, 5H, 2H), 4.38 (br s, 1H), 4.06 (br s, 1J=13.7 Hz, 2H), 3.45 (br t, 1J=7.0 Hz, 1H), 2.03-1.68 (m, 4H); [α]^{25}_{D}^{25}+34° (MeOH, c=1); HRMS calculated for C_{15}H_{28}NO₃ 261.1356, found 261.1356.
raphy using 7% aceton in methylene chloride afforded the title compound (45%) as a white solid: mp 157.0–160.0°C, 13C NMR (acetone-d₆) δ 159.3, 139.5, 134.6, 132.9, 130.3, 128.1, 119.9, 118.8, 115.0, 69.4, 53.7, 40.7; [α]D²⁵ =+28° (MeOH, c=1); HRMS calculated for C₁₂H₁₉BrF₃N₅O₇, 356.9827, found 365.9824.

EXAMPLE 9

General Synthesis of N-trifluoroacetoxylaminobenzene

To a stirred solution of the aniline (2.00 mmol) and pyridine (0.18 mL, 2.22 mmol, 1.1 eq) in anhydrous methylene chloride (10 mL) at 0°C under a nitrogen atmosphere is added stepwise trifluoroacetic anhydride (0.31 mL, 2.19 mmol, 1.1 eq). The resultant reaction mixture is stirred at 0°C under a nitrogen atmosphere for 3 hours. Water is added (15 mL), and this aqueous mixture is extracted with ethyl acetate (3×15 mL). The extracts are combined, dried (mgSO₄), and evaporated under reduced pressure. If necessary, the residue is column chromatographed using silica gel (approximately 50 g) and elution with an ethyl acetate gradient in hexanes to afford the corresponding N-trifluoroacetoxylaminobenzene.

Using this procedure the following compound was prepared:

4-(2-Oxo-1,3-oxazolidin-4-ylmethyl)-1-trifluoroacetoxylaminobenzene

4-(2-Oxo-1,3-oxazolidin-4-ylmethyl)-1-aminobenzene (WO 91/18897) was used. Column chromatography using 1:1 ethyl acetate/hexanes followed by ethyl acetate afforded the title compound (70%) as a white, crystalline solid: mp 132.0–136.0°C; Rf =0.35 in ethyl acetate; [α]D²⁵ =+14° (MeOH, c=1); Anal. calcd for C₁₂H₁₁N₂F₂O₄, C, 50.01; H, 3.85; N, 9.72. Found: C, 50.29; H, 3.81; N, 9.67.

EXAMPLE 10

5-(2-Benzylxycarbarnoamin-2-methoxy carbonyl ethenyl-1-yl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole

5-Bromo-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole (4.65 g, 15.9 mmol), N-benzylxycarbarno-dehydronalane methyl ester (5.0 g, 21.3 mmol), tri-i-o-tolyl phosphine (1.4 g, 4.6 mmol), palladium (II) acetate (350 mg, 1.6 mmol) and triethylamine (4.7 mL, 33.8 mmol) were dissolved in acetonitrile (50 mL) and heated at reflux with stirring under nitrogen overnight. After cooling to room temperature, the reaction mixture was partitioned between ethyl acetate and 2M aqueous sodium carbonate. The organic phase was washed with brine, dried (Na₂SO₄) and evaporated under reduced pressure. The resulting residue was purified by column chromatography on silica gel, eluting with a gradient of dichloromethane/ethanol (100:0 to 80:15), to yield 1.4 g of the title compound as a foam: Rf =0.3 dichloromethane:methanol:0.880 aqueous ammonia (90:10:1); 1H NMR (CDCl₃) δ 8.02 (br s, 1H), 7.38 (s, 1H), 7.50 (d, 1H), 7.03–7.00 (m, 2H), 6.49 (br s, 1H), 5.30 (s, 0.02H, CH₂Cl₂), 5.20–5.06 (m, 2H), 3.90–3.75 (br s, 3H), 3.28–3.14 (m, 2H), 2.75–2.45 (m, 5H), 2.32–2.20 (m, 1H), 1.90–1.54 (m, 4H). Anal. calcd for C₂₂H₂₁NO₅·0.1 CH₂Cl₂, C, 65.07; H, 5.60; N, 9.12. Found: C, 67.94; H, 6.51; N, 9.29.

EXAMPLE 11

5-(2RS,3-Amino-2-methoxy carbonyl ethyl)-3-(N-methyl pyrrolidin-2-yl)-1H-indole

5-(2-Benzylxycarbarnoamin-2-methoxy carbonyl ethenyl-1-yl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole (150 mg, 0.34 mmol) was dissolved in ethanolic hydrogen chloride (prepared from ethanol (4 mL) and acetyl chloride (0.048 mL, 0.68 mmol)) and the resulting solution was hydrogenated over 10% palladium-on-carbon (100 mg) at room temperature at a pressure of hydrogen of 15 psi overnight. The reaction mixture was filtered through a pad of Abarcell and evaporated under reduced pressure. The residue was partitioned between ethyl acetate and 2M aqueous sodium carbonate, the aqueous phase was extracted with ethyl acetate and the combined organic phases washed with brine, dried (Na₂SO₄) and evaporated under reduced pressure. The resulting residue was purified by column chromatography on silica gel, eluting with dichloromethane: ethanol gradient (90:10 to 80:20), followed by a gradient of dichloromethane:methanol:0.880 aqueous ammonia (80:20:0 to 80:20:1), yielding 60 mg of the title compound as a gum: Rf =0.2 dichloromethane:methanol:0.880 aqueous ammonia (90:10:1); [α]D²⁵ =+73° (c=0.1, CH₃OH); 1H NMR (CDCl₃) δ 8.78 (br s, 1H), 7.37 (s, 1H), 7.24 (d, 1H), 7.00–6.96 (m, 2H), 5.28 (s, 0.2H, CH₂Cl₂), 3.82–3.78 (m, 1H), 3.72 (s, 3H), 3.25–3.18 (m, 3H), 3.00–2.92 (m, 1H), 2.62–2.56 (m, 1H), 2.5–2.4 (m, 4H), 2.26–2.18 (m, 1H), 1.9–1.5 (m, 6H). Anal. calcd for C₂₆H₂₁NO₅·0.1 CH₂Cl₂·C, 67.71; H, 7.84; N, 12.97. Found: C, 66.57; H, 7.96; N, 12.77.

EXAMPLE 12

5-(2RS-Amino-3-hydroxyprop-1-yl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole

5-(2RS,3-Amino-2-methyloxy carbonyl ethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole (0.57 g, 1.8 mmol) was dissolved in ethanol (2.5 mL) and water (2.5 mL) and the resulting solution was added slowly to a stirred suspension of sodium borohydride (72 mg, 1.9 mmol) in water (2.5 mL) and ethanol (2.5 mL) at 0°C. The solution was heated at reflux for 3 hours and cooled to room temperature. After evaporation under reduced pressure, the resulting residue was extracted with dichloromethane (8x30 mL), the extract filtered to remove solid material, and the filtrate was evaporated under reduced pressure. The resulting residue was azetroped with dichloromethane (2x) to yield 130 mg of the title compound as a white foam: Rf =0.1 dichloromethane:methanol:0.880 aqueous ammonia (90:10:1); 1H NMR (CDCl₃) δ 8.02 (br s, 1H), 7.38 (s, 1H), 7.50 (d, 1H), 7.03–7.00 (m, 2H), 5.30 (s, 0.66H, CH₂Cl₂), 3.70–3.65 (m, 2H), 3.44–3.38 (m, 3H), 3.20–3.10 (m, 3H), 2.95–2.88 (m, 1H), 2.70–2.55 (m, 2H), 2.50–2.38 (m, 4H), 2.26–2.18 (m, 1H), 1.90–1.00 (m, 7H). Anal. calcd for C₂₂H₂₃NO₅·0.33 CH₂Cl₂·C, 65.94; H, 8.19; N, 13.31. Found: C, 65.75; H, 8.28; N, 12.93.

EXAMPLE 13

5-(2-Oxo-1,3-oxaolidin-4R,5-S-methylthyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole

5-(2-Oxo-1,3-oxaolidin-4R,5-S-methylthyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole (50 mg, 0.17 mmol) was dissolved in toluene (2.5 mL). Potassium hydroxide (50 mg) was dissolved in water (0.8 mL) and this solution added to the above toluene solution. The resulting mixture was cooled (ice-bath) and a solution of phosgene in toluene (12.5%, 0.56 mL) was added with stirring. After cooling with an ice-bath for 15 minutes, the reaction was stirred at room temperature overnight. The organic phase was separated, the aqueous layer extracted with ethyl acetate and then dichloromethane, and all organic phases were evaporated under reduced pressure, to yield a white foam.
Purification by column chromatography on silica gel, eluting with dichloromethane followed by a gradient of dichloromethane:methanol:0.880 aqueous ammonia (90:10:1 to 70:30:2), yielded 15 mg of the title compound: \( R_7 \text{=0.7} \) in dichloromethane:methanol:0.880 aqueous ammonia (70:30:2); \(^1\)H NMR (CDCl\(_3\)) 8 8.35 (br t, 1H), 7.40–7.28 (m, 2H), 7.05 (s, 1H), 6.96 (d, 1H), 5.42 (br d, 1H), 5.30 (s, 1H, CH\(_2\)Cl), 4.50–4.42 (m, 1H), 4.22–4.14 (m, 2H), 3.22–3.15 (m, 2H), 3.02–2.88 (m, 2H), 2.75–2.40 (m, 5H), 2.35–2.20 (m, 1H), 1.90–1.50 (m, 4H). Anal. calc'd for C\(_{16}\)H\(_{23}\)N\(_3\)O\(_5\): 62.43; H, 6.80; N, 11.81. Found: C, 62.66; H, 6.26; N, 11.71.

What is claimed is:

1. A compound of the formula

   \[
   W-(CH_2)_n Y-\text{Z}-R_11
   \]

   where \( W \) is

   (i) (ii) (iii) (iv) (v) (vi) (vii)

   and \( Y \) and \( G \) are each independently oxygen or sulfur; \( Z \) is —NH; \( R_1 \) is hydrogen, \( C_1 \) to \( C_8 \) alkyl, substituted \( C_1 \) to \( C_8 \) alkyl substituted with one hydroxy, \( C_3 \) to \( C_5 \) alkenyl, \( C_5 \) to \( C_8 \) alkynyl, aryl, \( C_1 \) to \( C_5 \) alkylarlyl, or —O—R; \( R_2 \) and \( R_3 \) are each independently hydrogen, \( C_1 \) to \( C_8 \) alkyl, aryl, or \( C_1 \) to \( C_5 \) alkylarlyl; \( R_4 \) is cyano, trifluoromethyl, —CO_2H, —CONH, —OH, —OCH_3, or —O-phenyl. 2. The compound of claim 1, wherein the compound of formula I is

3. The compound of claim 2, wherein the compound is the cis epimer.

4. The compound of claim 1, wherein the compound of formula I is the S epimer having the chiral carbon designated by #.

5. The compound of claim 1, wherein \( G \) is oxygen.

6. The compound of claim 1, wherein \( W \) is (i), (ii), (iii), or (iv); \( R_1 \) is hydrogen, \( C_1 \) to \( C_8 \) alkyl, aryl, \( C_1 \) to \( C_5 \) alkylarlyl, \( C_1 \) to \( C_5 \) alkylheteraryl, or —O—R; and \( R_2 \) is cyano, trifluoromethyl, —CO_2H, —CONH, —OH, —OCH_3, or —O-phenyl.

7. The compound of claim 6, wherein the compound of formula I is
8. The compound of claim 7, wherein the compound is the cis epimer.

9. The compound of claim 6, wherein the compound of formula I is the S epimer having the chiral carbon designated by #.

10. The compound of claim 1, wherein W is (i), (ii), or (iii); n is 1; m is 1; R₁ is hydrogen, C₁ to C₃ alkyl, or —CH₂CH₂OCH₃; R₂ is hydrogen; and R₃ is hydrogen or —CH₃Ph.

11. The compound of claim 10, wherein the compound of formula I is

12. The compound of claim 11, wherein the compound is the cis epimer.

13. The compound of claim 10, wherein the compound of formula I is the S epimer having the chiral carbon designated by #.

14. A pharmaceutical composition for treating a condition selected from hypertension, depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain, and chronic paroxysmal hemicrania and headache associated with vascular disorders comprising an amount of a compound according to claim 1 effective in treating such condition and a pharmaceutically acceptable carrier.

15. A pharmaceutical composition for treating disorders arising from deficient serotonergic neurotransmission comprising an amount of a compound according to claim 1 effective in treating such a disorder and a pharmaceutically acceptable carrier.

16. A method for treating a condition selected from hypertension, depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain, and chronic paroxysmal hemicrania and headache associated with vascular disorders comprising administering to a mammal requiring such treatment an amount of a compound according to claim 1 effective in treating such condition.